Nuvilex CEO and COO to Sit for Recorded Interview at 50th Annual ASCO Conference This Weekend
May 28 2014 - 9:00AM
Marketwired
Nuvilex CEO and COO to Sit for Recorded Interview at 50th Annual
ASCO Conference This Weekend
NEW YORK, NY--(Marketwired - May 28, 2014) - After traveling all
over the globe for the better part of the last two months putting
the pieces in place for its two-pronged attack on pancreatic
cancer, Nuvilex (OTCQB: NVLX) CEO Kenneth L. Waggoner and COO Dr.
Gerald W. Crabtree will once again hit the road. This time it's
Chicago and the American Society of Clinical Oncology (ASCO) 50th
annual conference which begins Friday, May 30 through June 3.
While at the ASCO conference this weekend, Nuvilex's CEO and COO
have agreed to sit for a recorded interview with Stock Market Media
Group to discuss:
- Upcoming Phase 2b clinical trials with CRO Clinical Network
Services (CNS),
- Preclinical studies and clinical trials studying symptoms
associated with pancreatic cancer with CRO Translational Drug
Development (TD2),
- Funding for Phase 2b and preclinical and clinical trials,
- Opportunity to work with 2 world renowned oncologists,
- What's left to complete and when will the Phase 2b trial
begin,
- What prompted the "two-prong attack" to also study symptoms
associated with pancreatic cancer, and other topics regarding
Nuvilex's short term future.
The ASCO Annual Meeting brings together more than 25,000
oncology professionals from a broad range of specialties, and will
serve as the ideal backdrop for an interview with a company that is
set to begin its work on pancreatic cancer. The recorded interview
will be available at www.stockmarketmediagroup.com next week.
About Stock Market Media Group SMMG is a Research and Content
Development IR firm offering a platform for corporate stories to
unfold in the media with Reports, Interviews and Articles. SMMG is
compensated for Nuvilex content by a third party who reserves the
right to buy, sell or remain neutral on securities after the
publication of this article. SMMG has received total compensation
of $91,160 for content related to Nuvilex. Additionally, a
principal at SMMG currently owns 200,000 total shares of Nuvilex
issued by the company through a consulting agreement which has
since ended for work unrelated to content development. The shares
have been held for the requisite period under Rule 144 as of
October 31, 2013 and April 30, 2014, and are eligible to be sold
immediately without further notice. For more information:
www.stockmarketmediagroup.com.
Contact: Stock Market Media Group Email Contact